Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5022-5025

  Mar Rodriguez M ^a   Javier Pastor, F ^a   Calvo, Enrique ^a   Salas, Valentina ^a   Sutton, Deanna A ^b   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CEFTAZIDIME; CYCLOPHOSPHAMIDE; FLUOROURACIL; POSACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIAL INFECTION; BLOOD LEVEL; BROTH DILUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; FUNGAL STRAIN; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS; RHIZOPUS MICROSPORUS INFECTION; SINGLE DRUG DOSE;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BRAIN; KIDNEY; MALE; MICE; MUCORMYCOSIS; RHIZOPUS; TRIAZOLES;

EID: 71249087152     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01026-09     Document Type: Article

References (23)

1. Alastruey-Izquierdo, A., M. V. Castelli, I. Cuesta, A. Monzon, M. Cuenca- Estrella, and J. L. Rodriguez-Tudela. 2009. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob. Agents Chemother. 53:1686-1689.
2. Almyroudis, N. G., D. A. Sutton, A. W. Fothergill, M. G. Rinaldi, and S. Kusne. 2007. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob. Agents Chemother. 51:2587-2590.
3. Alvarez, E., D. A. Sutton, J. Cano, A. W. Fothergill, A. Stchigel, M. G. Rinaldi, and J. Guarro. 2009. Spectrum of zygomycete species identified in clinically significant specimens in the United States. J. Clin. Microbiol. 47: 1650-1656.
4. Chayakulkeeree, M., M. A. Ghannoum, and J. R. Perfect. 2006. Zygomycosis: the re-emerging fungal infection. Eur. J. Clin. Microbiol. Infect. Dis. 25:215-229.
5. Connolly, P., J. Wheat, C. Schnizlein-Bick, M. Durkin, S. Kohler, M. Smedema, J. Goldberg, E. Brizendine, and D. Loebenberg. 1999. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. 43:322-328.
6. Dannaoui, E., J. F. G. M. Meis, D. Loebenberg, and P. E. Verweij. 2003. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47:3647-3650.
7. de Mol, P., and J. F. G. M. Meis. 2009. Disseminated Rhizopus microsporus infection in a patient on oral corticosteroid treatment: a case report. Neth. J. Med. 67:25-28.
8. Greenberg, R. N., K. Mullane, J. A. van Burik, I. Raad, M. J. Abzug, G. Anstead, R. Herbrecht, A. Langston, K. A. Marr, G. Schiller, M. Schuster, J. R. Wingard, C. E. Gonzalez, S. G. Revankar, G. Corcoran, R. J. Kryscio, and R. Hare. 2006. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50:126-133.
9. Ibrahim, A. S., T. Gebremariam, J. A. Schwartz, J. E. Edwards, Jr., and B. Spellberg. 2009. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob. Agents Chemother. 53:772-775.
10. Krishna, G., A. Moton, L. Ma, M. M. Medlock, and J. McLeod. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966.
11. Messer, S. A., D. J. Diekema, R. J. Hollis, L. B. Boyken, S. Tendolkar, J. Kroeger, and M. A. Pfaller. 2007. Evaluation of disk diffusion and Etest compared to broth microdilution susceptibility testing of posaconazole against clinical isolates of filamentous fungi. J. Clin. Microbiol. 45:1322-1324.
12. Morris, M. I. 2009. Posaconzaole: a new oral antifungal agent with an expanded spectrum of activity. Am. J. Health Syst. Pharm. 66:225-236.
13. NCCLS/CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard, 2nd ed. Document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Peel, T., J. Daffy, K. Thursky, P. Stanley, and K. Buising. 2008. Posaconazole as first line treatment for disseminated zygomycosis. Mycoses 51:542-545.
15. Pitisuttithum, P., R. Negroni, J. R. Graybill, B. Bustamante, P. Pappas, S. Chapman, R. S. Hare, and C. J. Hardalo. 2005. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 56:745-755.
16. Rodríguez, M. M., E. Calvo, C. Serena, M. Mariné, F. J. Pastor, and J. Guarro. 2009. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob. Agents Chemother. 53:2153-2155.
17. Rodríguez, M. M., C. Serena, M. Mariné, F. J. Pastor, and J. Guarro. 2008. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob. Agents Chemother. 52:3786-3788.
18. Rogers, T. R. 2008. Treatment of zygomycosis: current and new options. J. Antimicrob. Chemother. 61(Suppl. 1):i35-i40.
19. Rüping, M. J. G. T., N. Albermann, F. Ebinger, I. Burckhardt, C. Beisel, C. Müller, J. J. Vehreschild, M. Kochanek, G. Fätkenheuer, C. Bangard, A. J. Ullmann, W. Herr, K. Kolbe, M. Hallek, and O. A. Cornely. 2008. Posaconazole concentrations in the central nervous system. J. Antimicrob. Chemother. 62:1468-1470.
20. Simitsopoulou, M., C. Gil-Lamaignere, N. Avramidis, A. Maloukou, S. Lekkas, E. Havlova, L. Kaurounaki, D. Loebenberg, and E. Roilides. 2004. Antifungal activities of posaconazole and granulocyte-macrophage colonystimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob. Agents Chemother. 48:3801-3805. (Pubitemid 39304606)
21. Spellberg, B., T. J. Walsh, D. P. Kontoyiannis, J. E. Edwards, Jr., and A. S. Ibrahim. 2009. Recent advances in the management of mucormycosis: from bench to bedside. Clin. Infect. Dis. 48:1743-1751.
22. Tobón, A. M., M. Arango, D. Fernández, and A. Restrepo. 2003. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis. 36:1488-1491.
23. van Burik, J. A. H., R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P. Kontoyiannis. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42:e61-e65.